Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005 |
Resumo: | Introduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohns disease and on best practice in topics of current interest in Crohns disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohns disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohns disease of any localization with initial duration of treatment varying according to patients response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms. |
id |
RCAP_5ba6e65ad55c907432a3ec77e0b72253 |
---|---|
oai_identifier_str |
oai:scielo:S0872-81782012000400005 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting resultsInflammatory bowel diseaseorticosteroidsCrohns diseaseConsensusIntroduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohns disease and on best practice in topics of current interest in Crohns disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohns disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohns disease of any localization with initial duration of treatment varying according to patients response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms.Sociedade Portuguesa de Gastrenterologia2012-07-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005Jornal Português de Gastrenterologia v.19 n.4 2012reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005Magro,FernandoCravo,MariliaLago,PaulaMinistro,PaulaPeixe,PaulaPortela,FranciscoRamos,JaimeTavares,Lourdesinfo:eu-repo/semantics/openAccess2024-02-06T17:09:10Zoai:scielo:S0872-81782012000400005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:21:17.122514Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
title |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
spellingShingle |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results Magro,Fernando Inflammatory bowel disease orticosteroids Crohns disease Consensus |
title_short |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
title_full |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
title_fullStr |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
title_full_unstemmed |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
title_sort |
Portuguese consensus on the best practice for the management of inflammatory bowel disease: IBD ahead 2010 meeting results |
author |
Magro,Fernando |
author_facet |
Magro,Fernando Cravo,Marilia Lago,Paula Ministro,Paula Peixe,Paula Portela,Francisco Ramos,Jaime Tavares,Lourdes |
author_role |
author |
author2 |
Cravo,Marilia Lago,Paula Ministro,Paula Peixe,Paula Portela,Francisco Ramos,Jaime Tavares,Lourdes |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Magro,Fernando Cravo,Marilia Lago,Paula Ministro,Paula Peixe,Paula Portela,Francisco Ramos,Jaime Tavares,Lourdes |
dc.subject.por.fl_str_mv |
Inflammatory bowel disease orticosteroids Crohns disease Consensus |
topic |
Inflammatory bowel disease orticosteroids Crohns disease Consensus |
description |
Introduction: The treatment of inflammatory bowel disease (IBD) has focussed on the management of symptoms but is becoming more resolute on changing the course of the disease and its complications in the long-term. In order to minimize the development of complications and to improve outcomes for these patients it is important to develop other strategies to manage IBD and to optimize current clinical practice. Objective: This article reports the main consensus statements reached during the Portuguese National Meeting on improvement of disease control in IBD, on optimization of corticosteroid and immunosuppressive use in Crohns disease and on best practice in topics of current interest in Crohns disease. Methods: An International Steering Committee selected the top 10 most important unanswered practical questions on the use of conventional therapy in Crohns disease, to be debated and analysed in several National Meetings of different countries. In each country a National Steering Committee (NSC) was created to moderate a National Meeting during which several expert groups answered the selected questions in light of their clinical practice. Answers were classified according to the Oxford levels of evidence. Consensus: A general consensus was obtained, some of the conclusions were as follows. It is important to introduce conventional corticosteroids in moderate to severely active Crohns disease of any localization with initial duration of treatment varying according to patients response; the best option to prevent steroid-induced side effects is to avoid its prolonged or repetitive use and switching appropriate patients to immunosuppressive therapy. Initiation of immunomodulators early in the disease course should be considered for patients with a poor prognosis and optimal safety monitoring was discussed, with the need to reassess patients at appropriate timepoints, make corticosteroid-free remission a goal and treat beyond symptoms. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-07-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000400005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Gastrenterologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Gastrenterologia |
dc.source.none.fl_str_mv |
Jornal Português de Gastrenterologia v.19 n.4 2012 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817551354685554688 |